• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Executive Moves: Novavax

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Catalent Biologics Completes Madison Expansion
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Ensuring Pharma Manufacturing Quality

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion

    Ascendia Pharmaceuticals Poised for Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    PCI Pharma Services

    Emergent BioSolutions

    Almac Group

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Syngene

    Alcami

    PCI Pharma Services

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    CEO Spotlight: Salim Haffar

    The chief executive talks industry trends, challenges and what’s in store for PCI Pharma Services as it continues its rapid growth and global expansion strategy

    CEO Spotlight: Salim Haffar
    PCI Pharma Services' chief executive officer, Salim Haffar
    CEO Spotlight: Salim Haffar
    Related CONTENT
    • Asymchem
    • Legacy Pharma Solutions
    • PCI Pharma Services
    • Catalent Pharma Solutions
    • Regis Custom Pharma
    Tim Wright, Editor, Contract Pharma04.05.19
    PCI Pharma Services is an integrated full service contract manufacturing organization (CMO) capable of taking compounds from the earliest stages of development through to commercialization. Its core services support each stage of the product lifecycle, including drug development, clinical trial supply, commercial launch and ongoing commercial supply.

    Over the past decade, the Philadelphia-based CMO has undergone rapid growth of its services portfolio while expanding its global reach through acquisitions. In 2018, PCI bought Pharmaceutical Packaging Professionals (PPP) in Melbourne in March, providing new access to Australia and the wider Asia-Pacific region. Then in September it struck a deal for Sherpa Clinical Packaging in San Diego, CA, extending its presence across the U.S. to the West Coast and bolstering its presence in the biopharmaceutical development space.

    During the year, PCI also underwent some internal change when it announced in July that Salim Haffar would join the company as its new chief executive officer. He brings to the chief executive role more than 20 years of experience in the pharmaceutical industry. At the time of the announcement, he was serving as president of Aptar Pharma, where he oversaw the company’s growth strategy and journey to become a leading global provider of drug delivery systems across three end markets—prescription, consumer healthcare and injectables.

    He officially took hold of PCI’s reins in September, just as the Sherpa deal was going down. Contract Pharma had the chance to talk with Salim recently about the acquisition, PCI’s plans for the future and industry trends and challenges in general. 

    Contract Pharma (CP): You joined PCI just ahead of the Sherpa acquisition. Can you give some insight into that deal and how it expands PCI’s capabilities?

    Salim Haffar (SH):
    It started with a strategic goal to continue to grow and expand our clinical business on the West Coast where a lot of biopharma research and development activity is taking place. It really allows us to expand further into the early phases of drug development and expand our pipeline and better partner with our biopharma customers. The acquisition was the next logical step in our clinical services expansion strategy, further enhancing our development-stage capabilities and geographic presence. The addition of the San Diego business complements an amazing early phase business in Australia, bolstering a comprehensive offering for speed in initiating early phase studies for our clients. It broadens PCI’s strengths and provides a real depth of continuity for clients in a molecule-to-market portfolio of services.

    CP: When did PCI choose to focus more efforts on expanding the clinical side of its business?

    SH:
    PCI has really been focusing on expanding its clinical business for close to a decade now. First, by building the capability internally through our talent base and expanding our Rockford, IL facility. PCI’s also been on the acquisition trail for some time, buying companies like Biotec, which goes back to 2014. More recently, we acquired Dublin-based Millmount Healthcare, expanding PCI’s packaging capabilities in the EU. We then established an Asia-Pacific HQ and strengthened our position in the market with the acquisition of Melbourne, Australia-based Pharmaceutical Packaging Professionals (PPP). And, of course, Sherpa was the most recent piece of the puzzle to build our clinical business, enabling our expansion to the U.S. West Coast.

    CP: Earlier this year PCI unveiled a $20 million investment to expand its biotech technologies including advanced injectable delivery forms. What does this investment entail?

    SH:
    For years PCI has been at the forefront of packaging, testing and releasing branded biologic drug product. We now must also cater to a large customer base of biosimilars. The $20 million investment we are making is going to add expanded biotech clinical and commercial packaging and release testing capability at our Center of Excellence in Philadelphia. We will also expand cold chain capacity at numerous global sites to support our biotech infrastructure, both refrigerated as well as expand frozen and cryogenic temperatures. This latest investment will also include capacity expansion for cutting edge technologies for the labeling and assembly of state-of-the-art safety syringes, autoinjectors and pen devices with integrated high speed cartoning, and in-line serialization. This investment will help customers both in the clinical stage as well as the commercial stage. Leveraging this clinical-to-commercial expertise is a huge advantage for our clients, allowing us to best position them for success in development and commercialization.

    CP: What about investment in PCI’s legacy business?

    SH:
    In addition to the acquisitions we’ve discussed, PCI has undergone a lot of expansion in its existing legacy business. We are building a brand new dedicated and expanded clinical center in what I call our Mother Ship—the Rockford, IL site. We’re making this one of our largest clinical centers to serve a large customer base by adding 30,000 additional square feet of space in support of primary and secondary packaging and labeling operations for investigational medicinal products at the Clinical Services Center of Excellence.

    The expanded building, which is expected to open for business in late 2019 following internal fit-out and a period of validation and licensing, will provide increased flexibility to meet customer needs. Purpose-built for scalable primary and secondary packaging and labeling, the new packaging suites offer maximum flexibility, with the ability to operate on either a stand-alone or integrated basis across suites. The build will feature a state-of-the-art 2-8°C packaging room for cold chain products. Additionally, the expansion will include a reception area and will double the current office space to meet staff growth plans, demonstrating our commitment to investment in a leading position to support clients’ global clinical trial supply needs.

    The Rockford site is also undergoing a bottling line capacity expansion for commercial packaging. Construction of the additional packaging suites began in March 2018 to add considerable footprint for primary and secondary packaging operations equipped with high speed tablet filling, cartoning, as well as in-line serialization and aggregation. The new expansion will grow the bottling operation in Rockford by producing an extra 100 million bottles per year. Also worth noting, PCI is undertaking an significant expansion of the Rockford segregated potent compound packaging site, a stand-alone facility that supports these unique molecules, often in oncology, that require specialized high containment infrastructure and processes. This expansion furthers investment we have made in a complementary site in Dublin.

    CP: What are some other business highlights from the past 12 months?

    SH:
    We recently unveiled an investment in our infrastructure for packaging of controlled substances, complementing our capacity for blister packaging, a key tenet of recent calls for dispensing opioid prescriptions in limited quantity unit dose packaging as a tactic to combat substance misuse. We’ve extended onsite controlled substance storage at our commercial packaging locations in Philadelphia and Rockford and will undertake further expansions as demand increases for these specialized requirements. PCI supports DEA Schedule I-V controlled substances for both commercial prescription medicines, as well as those for investigational clinical trials, with approximately two million square feet of dedicated packaging infrastructure across the two locations.

    We’re also investing in adding clinical stage manufacturing capabilities at our Melbourne facility for injectable dose fill-finish. We are also investing heavily in our Dublin facility to support expansion across the base of clinical operations, in addition to commercial packaging and product release. There is a need to expand our European business driven by customer demand, but also to some degree in response to the Brexit situation. However, the greatest opportunity long term, is the expansion of our European footprint outside the UK.

    Moving forward PCI will continue to engage in good high levels investments, as well as modernize our facilities with the latest technological advancements. More importantly, we’re investing in talent too.

    CP: Speaking of technology, what are some of PCI’s most recent technological breakthroughs?

    SH:
    We’re introducing a lot of automation capabilities across our sites with the help of sophisticated, high-speed testing and manufacturing equipment. This includes advanced robotics, an exciting use of technology for which we see broad opportunity to pioneer new processes. We are also investing in high containment manufacturing for high potency drugs including environments for controlled substances or very high potent and/or sophisticated specialty pharma customers that require very special manufacturing environmental settings. The packaging locations we have invested in for both the U.S. (Rockford) and Europe (Dublin) are truly industry leading high containment solutions for our clients challenging molecules.

    CP: What are some of the crucial issues impacting pharma/biopharma manufacturing and supply and CDMOs in particular?

    SH:
    Pricing continues to be a major issue. For a number of years there existed a branded biologic drug base that was clearly highly differentiated, creating really great value to patients while addressing a large number of unmet medical needs, from autoimmune diseases to certain types of cancers. As the pressure on healthcare costs increases, as well as competition with the arrival of biosimilars, the challenge we face is how to reduce drug costs. Not just the manufacturing costs of the drug, but the whole ecosystem from drug development all the way through to manufacturing and commercialization. This is where the industry is facing its biggest challenge: the impact of increasing R&D and regulatory costs and the pressure that is putting on margins and prices.

    This is where strong partnerships with CDMOs are invaluable for pharma and biopharma. Customers want to see a track record and a high level of expertise that can serve as the foundation for a trusted partnership that can be sustained for many years.

    Customers come to us and really want us to become part of the solution to help them address problems they are facing. We are the experts in finding efficiencies, reducing costs, and also leveraging our own investments so they can invest their dollars into their own core expertise, such as research and development.

    So while the current pricing model, and how it cascades down the value chain, presents one big challenge affecting the whole industry, it’s also an opportunity for CDMOs to be part of the solution.

    CP: How will the product mix between small molecules and biologics unfold?

    SH:
    For the past 5-10 years a large portion of the drugs under development are biologics and biosimilars, which requires a different set of capabilities around drug development and API manufacturing, as well as providing clinical trial support, commercial packaging and release testing and so on, all the way through to distribution. It’s a whole new supply chain requiring different capabilities, changing the market needs and expectations versus older dosage forms like tablets and capsules and blistering. The growth trend of large molecules is not going to slow down, so it’s adding complexity in the supply chain.

    At the same time, small molecules are becoming more complex with the emergence of  highly potent and toxic drugs that require different manufacturing environments for specialty pharma firms. On the small molecule side we will continue to see the emergence of more complex dosage forms, particularly in oncology, a huge opportunity.

    Again, this is where CDMOs are coming in and providing solutions for their customers so they can focus on research and sales and marketing and not on having to build that sort of capability and capacity in house, creating a pathway for amazing new medicines to be delivered to patients around the world.

    CP: Lastly, how are partnerships in external development and manufacturing evolving, and what does the future hold?

    SH:
    Partnerships continue to evolve, but some are still around very basic principles. Having a high level of expertise and a proven track record that stands the test of time are the two fundamentals any pharma company, small or large, continues to look for when embarking on a partnership. Because, at the end of the day, a partnership is about trusting your drug product—whether it’s in the clinical, manufacturing or commercial stage—to a partner. So it’s a huge decision to make.

    A third factor important in a successful partnership is displaying pure transparency around your capabilities. A lot more pharma customers are looking to companies like PCI to partner on the basis of us providing them expanded capabilities. Whether it’s geographic presence or whether it’s particular expertise or capability or technology they would like to have. Not just for today, but for their future drug pipeline. They are depending on us and it is important for them to know we have the capabilities and will continue to add capabilities to support their efforts.

    As the regulatory rigor and the quality expectations continue to impact the pharma and biopharma industry moving forward, only those service providers who can demonstrate these basic fundamental skills will survive because the complexity of the industry is only going to increase. 
    Related Searches
    • biosimilars
    • high containment
    • Filling
    • High Potency
    Suggested For You
    Asymchem Asymchem
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    Catalent Pharma Solutions Catalent Pharma Solutions
    Regis Custom Pharma Regis Custom Pharma
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Adare Pharma Solutions Adare Pharma Solutions
    PCI Invests in High Potent Tableting and Powder Modification Capacity PCI Invests in High Potent Tableting and Powder Modification Capacity
    PCI Appoints CFO PCI Appoints CFO
    Industry 4.0 in the Pharma Industry Industry 4.0 in the Pharma Industry
    TraceLink Launches Smart Inventory Tracker TraceLink Launches Smart Inventory Tracker
    Pfenex and Alvogen Expand Development Collaboration Pfenex and Alvogen Expand Development Collaboration
    PCI Appoints CHRO PCI Appoints CHRO
    PCI Expands Controlled Substance Storage Capacity PCI Expands Controlled Substance Storage Capacity

    Related Features

    • R&D
      Small Innovators & Niche CROs

      Small Innovators & Niche CROs

      Smaller CROs have the opportunity to provide a niche approach to its clients, particularly smaller sponsors who have shared synergies.
      Neil Goodman, David Bruce and Mohamed El Malt, Europital 04.01.21

    • Laboratory Testing
      Focus on Science

      Focus on Science

      How to maximize lab performance and value through comprehensive equipment management.
      Rohit Shroff, Senior Vice President, Global Lab Products, Avantor 04.01.21

    • Analytical Services | Bioanalytical Services | Laboratory Testing | R&D
      Rapid and Data Rich Chromatographic Method Development

      Rapid and Data Rich Chromatographic Method Development

      An overview of what to consider when developing chromatographic methods.
      Daniel Kirschner, Executive Director of Analytical Services, Cambrex - Durham, North Carolina 04.01.21


    • Preparing Your Post Pandemic Talent Strategy

      Preparing Your Post Pandemic Talent Strategy

      Areas for consideration for adopting the right approach to reinforce investments, optimize business and maximize your workforce.
      Neil Kelly, Managing Partner, Vector Partners 04.01.21

    • Laboratory Testing | R&D
      How Modern Near-Infrared Came to Be

      How Modern Near-Infrared Came to Be

      First region outside the visible to be discovered and last to be utilized.
      Gary E. Ritchie, Contributing Writer 04.01.21

    • APIs | Supply Chain
      Securing Your API Supply Chain: Three Keys to Success

      Securing Your API Supply Chain: Three Keys to Success

      Key considerations when outsourcing API procurement and supply chain management.
      Selwyn Lustman and Lina Cogan, LGM Pharma 04.01.21


    • Solid Dosage/Semi-solids
      Hygienic Packaging Technology

      Hygienic Packaging Technology

      Growing consumer demand for health products highlights hygienic packaging.
      John Brown, Vice President of Global Marketing, Selig 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21


    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21

    • Pharmaceutical Manufacturing  Equipment Trends

      Pharmaceutical Manufacturing Equipment Trends

      Demand for flexibility remains the driving force behind equipment systems.
      Kristin Brooks, Managing Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • Nutraceutical Manufacturing:  Meeting the Challenges of Today, Planning for  Tomorrow

      Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow

      Companies continue balancing high demand, supply disruption, and worker safety during the pandemic.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • 2021 Contract  Manufacturing Survey

      2021 Contract Manufacturing Survey

      Our fourth annual audience poll indicates continued reliance on manufacturing partners, particularly for small businesses.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • APIs
      Small Molecule Development Trends

      Small Molecule Development Trends

      A Q&A with Cambrex Edinburgh’s site director, Mark Benger.
      Tim Wright, Editor, Contract Pharma 03.01.21

    Trending
    • Astellas, Affinivax In Global MAPS Vax Pact
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Catalent Biologics Completes Madison Expansion
    • ANI Acquires Branded Products Portfolio From Sandoz
    Breaking News
    • Microbiologics Expands Virology Services
    • ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    • Executive Moves: Novavax
    • Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    • Catalent Biologics Completes Madison Expansion
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Four-Week Fish Oil Regimen Showed Significant Muscular Damage Protection in Recent Study
    Review Covers Role of Vitamin K2 in the ‘Calcium Paradox’
    KD Pharma Acquires Rohner AG Manufacturing Assets
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    Shepherd Color Unveils Bismuth Vanadate Yellow Pigment
    HMG Paints Reports Positive Feedback on Contract Matt Emulsion
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Vicarious Surgical Appoints CFO and Chief Legal Officer
    Nagarro Achieves ISO 13485 Certification
    MICRO Expands with New Facility in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Microbiologics Expands Virology Services
    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    Executive Moves: Novavax
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Cosmoprof Worldwide Bologna Postpones 2021 Show
    Native Launches Broad Spectrum SPF 30 Mineral Sunscreens
    Revieve Launches Skin Coach
    Happi

    Latest Breaking News From Happi

    Kao Launches Online Beauty Store in Europe
    Neutrogena Takes Action on Skin Health Disparities
    Babor Professional Skin Care Names McCaffrey as Vice President of Sales
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Maxcess updates user interface for Fife guiding Sensor
    Bobst announces virtual packaging industry event
    Edale appoints agent in Poland
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    PFNonwovens Adding New Capabilities in Znojmo
    Russ Torres Named Group President of Kimberly-Clark North America
    Aries Face Masks Meet ASTM Standards
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Global Bone Tumor Ablation Devices Market to Top $111 Million by 2027
    GreenBone Ortho Closes 10 Million Euros Series B Funding Round
    SynerFuse, Cirtec Medical Partner to Develop Back Pain Management Device
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations
    SUPERSMART Wins 'Best Publicly Funded Project Demonstrator' in 2021 OE-A Competition

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login